PYLARIFY AI™ enables accurate, efficient, and reproducible quantification of PYLARIFY® PET/CT scans1,2
PYLARIFY AI™ is the only FDA-cleared medical device to offer standardized quantitative and accurate reporting of PSMA PET/CT images, including those achieved using PYLARIFY® PET/CT.1 Standardized reporting of PSMA assessments can improve the management of prostate cancer patients, including the accurate quantification of disease burden with increased reproducibility on a patient level.1,2
Reproducible and Quantitative Disease-burden Indices2,3
- Improved inter-reader reproducibility in staging (κ >0.80) and quantification (ICC: 0.99) of prostate cancer patients2,3
- Quantitative PSMA scan index (PSI) was associated with PSA and Gleason Score2
Accurate Lesion Quantification3
- High segmentation and detection accuracy (>90%) for PSMA lesions in regional and distant lymph nodes3
- A quantitative PSMA score/index can help stratify patients for available treatment options2
- A quantitative PSMA score/index can accurately demonstrate disease progression and response2
- Significant efficiency in creating quantitative structure reporting, averaging 3-5 minutes for a comprehensive, quantitative report2
What does PYLARIFY AI™ report on?1,3
- PYLARIFY AI™ automatically analyzes the CT image to segment anatomical regions, including the liver and the thoracic part of the aorta, as reference organs
- Subsequently, PYLARIFY AI™ analyzes the PET image to detect target hotspots, regions (ROIs) of locally elevated PSMA tracer intensities indicative of suspicious tumor tissue and metastasis
- ROIs are marked by selecting from predefined hotspots or by manual drawing
- The selected lesions are labeled with type and location, and quantified in terms of standard uptake values (SUVs) for tracer uptake intensities and their respective volumes
- When used by radiology professionals, the standardized PYLARIFY AI™ report provides consistent and quantitative assessments of PSMA PET/CT images
Introducing the PSMA Scan Index (PSI)™2
- A unique quantitative assessment based on the unique physiological uptake of PSMA and inspired by recommended guidelines for PSMA assessment
How does PYLARIFY AI™ work?3
Deep-learning-enabled segmentation of anatomical context in low-dose CT of PSMA PET/CT
DESIGNED TO COMPLEMENT THE CLINICAL WORKFLOW
PYLARIFY AI™ deployment can be facilitated both as a secure web cloud application and as a local server application to secure private patient data.
Once deployed, the adaptive application can be integrated to the institution's image acquisition platforms or to the Picture Archiving and Communication Systems (PACS). The report generated from PYLARIFY AI™ is available in DICOM and JPG format and can be attached in the existing clinical impression for the physician’s review.
Seamless integration into existing clinical workflow (eg, linking to PACS) delivers a unique combination of clinical utility in a workflow-friendly package.
CT=computed tomography; PET=positron emission tomography; PSMA=prostate-specific membrane antigen; ROI=region of interest.
PYLARIFY® (piflufolastat F 18) Injection is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer:
- with suspected metastasis who are candidates for initial definitive therapy.
- with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level.
- FDA clearance letter for aPROMISE. Food and Drug Administration. July 27, 2021.
- Nickols N, Anand A, Johnsson K, et al. aPROMISE: a novel automated-PROMISE platform to standardize evaluation of tumor burden in 18F-DCFPyL (PSMA) images of veterans with prostate cancer [published online ahead of print, 2021 May 28]. J Nucl Med. 2021. doi:10.2967/jnumed.120.261863
- Johnsson K, Brynolfsson J, Sahlstedt H, et al. Analytical performance of aPROMISE: automated anatomic contextualization, detection, and quantification of [18F]DCFPyL (PSMA) imaging for standardized reporting [published online ahead of print, 2021 Aug 31]. Eur J Nucl Med Mol Imaging. 2021. doi:10.1007/s00259-021-05497-8